Antitumour efficacy of MEK inhibitors in human lung cancer cells and their derivatives with acquired resistance to different tyrosine kinase inhibitors

BACKGROUND: To study the molecular mechanisms regulating cancer cell resistance to four different tyrosine kinase inhibitors (TKIs): erlotinib, gefitinib, vandetanib and sorafenib. METHODS: An in vitro model of acquired resistance to these TKIs was developed by continuously treating the human lung a...

Descripción completa

Detalles Bibliográficos
Autores principales: Morgillo, F, Cascone, T, D'Aiuto, E, Martinelli, E, Troiani, T, Saintigny, P, De Palma, R, Heymach, J V, Berrino, L, Tuccillo, C, Ciardiello, F
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2011
Materias:
Translational Therapeutics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3172903/
https://www.ncbi.nlm.nih.gov/pubmed/21750552
http://dx.doi.org/10.1038/bjc.2011.244

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3172903/
https://www.ncbi.nlm.nih.gov/pubmed/21750552
http://dx.doi.org/10.1038/bjc.2011.244

Ejemplares similares